MedPath
HSA Product

MALARONE TABLET

Product approved by Health Sciences Authority (SG)

Basic Information

MALARONE TABLET

TABLET, FILM COATED

Regulatory Information

SIN09761P

May 16, 1998

Prescription Only

Therapeutic

ORAL

August 10, 2023

June 3, 2025

XP01BB51

Company Information

GLAXOSMITHKLINE PTE LTD

GLAXOSMITHKLINE PTE LTD

Active Ingredients

PROGUANIL HCl

Strength: 100 mg

ATOVAQUONE

Strength: 250 mg

Detailed Information

Contraindications

**4.3. Contra-indications** Malarone is contra-indicated in individuals with known hypersensitivity to atovaquone or proguanil hydrochloride or any component of the formulation. Malarone is contra-indicated for prophylaxis of _P. falciparum_ malaria in patients with severe renal impairment (creatinine clearance <30 ml/min).

Indication Information

**4.1. Therapeutic Indications** Malarone is a fixed-dose combination of atovaquone and proguanil hydrochloride which acts as a blood schizonticide. It is indicated for: - Prophylaxis of _Plasmodium falciparum_ malaria. - Treatment of _Plasmodium falciparum_ malaria. Because Malarone is effective against drug sensitive and drug resistant _P. falciparum_ malaria, it is especially recommended for prophylaxis and treatment of _P. falciparum_ malaria in areas where the pathogen may be resistant to other antimalarials. Official guidelines and local information on the prevalence of resistance to antimalarial drugs should be taken into consideration. Official guidelines will normally include WHO and public health authorities’ guidelines.

© Copyright 2025. All Rights Reserved by MedPath